Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 274 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacogenomics Clear all
Recruiting No phase listed Observational

IPGx PILOT Whole Genome Sequencing Extension Cohort

NCT06766071
View directory record Official record
Conditions
Adverse Drug Reaction (ADR), Polypharmacy Patients
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)

NCT05966142
View directory record Official record
Conditions
Chronic Pain
Interventions
Pharmacogenetic testing, Clinical decisions support
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

NCT00799396
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Coronary Heart Disease
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 26, 2026, 5:46 PM EDT
Withdrawn No phase listed Observational

Pharmacogenomics in Pulmonary Arterial Hypertension

NCT00593905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions
Sitaxsentan, Bosentan, Ambrisentan
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 26, 2026, 5:46 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813
View directory record Official record
Conditions
Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Quality-of-Life Assessment, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
781
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 509 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 26, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

NCT01907802
View directory record Official record
Conditions
BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 26, 2026, 5:46 PM EDT
Completed No phase listed Observational

Pharmacogenomic Profiling of Pediatric Patients

NCT02770339
View directory record Official record
Conditions
Mental Disorders, Metabolism Medication Toxicity, Pediatric Disorder
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 26, 2026, 5:46 PM EDT
Terminated No phase listed Observational

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

NCT00471653
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Thrombocytopenia
Interventions
temozolomide, comparative genomic hybridization, polymorphism analysis, laboratory biomarker analysis, pharmacological study, radiation therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Duarte, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 26, 2026, 5:46 PM EDT
Completed No phase listed Observational

Genetic Evaluation for Medication Selection (GEMS) Study

NCT03736057
View directory record Official record
Conditions
Dementia, Psychiatric Disorders Mood, Behavior Disorders
Interventions
Delayed results of pharmacogenomic results
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
40 participants
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nudge Strategies for DPYD Testing in Patients With Gastrointestinal Cancers Treated With Fluoropyrimidines

NCT06559462
View directory record Official record
Conditions
DPYD Gene Mutation, Gastrointestinal Cancer, Health Care Seeking Behavior
Interventions
Focus Group, Discrete Choice
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation

NCT04727827
View directory record Official record
Conditions
Hematopoietic Cell Transplantation, Oncology
Interventions
Pharmacogenomic-guided supportive care
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

NCT02631746
View directory record Official record
Conditions
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection, Lymphomatous Adult T-Cell Leukemia/Lymphoma, Smoldering Adult T-Cell Leukemia/Lymphoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 26, 2026, 5:46 PM EDT
Not yet recruiting Not applicable Interventional

Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients

NCT06744712
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Pharmacogenomic Testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 26 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

NCT00611351
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Genetic + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

NCT03216499
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
HIF-2alpha Inhibitor PT2385, Pharmacological Study, Laboratory Biomarker Analysis, Pharmacogenomic Study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

NCT01006733
View directory record Official record
Conditions
Thromboembolism
Interventions
Pharmacogenetic, Target INR 1.8
Genetic · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 26, 2026, 5:46 PM EDT
Not listed Phase 2 Interventional

Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma

NCT00292955
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Cetuximab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 26, 2026, 5:46 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes

NCT02932579
View directory record Official record
Conditions
Pain
Interventions
Pharmacogenomic Testing, Ibuprofen, hydroxycontin/acetominophen, acetominophen, Oxycontin/acetominophen
Other · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 26, 2026, 5:46 PM EDT
Completed No phase listed Observational

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

NCT01886404
View directory record Official record
Conditions
HIV Infection
Interventions
Efavirenz
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey

NCT05037305
View directory record Official record
Conditions
Pharmacogenomic Testing
Interventions
Educational video
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
798 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Completed No phase listed Observational Results available

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

NCT01632267
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Not listed
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00770471
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, veliparib, DNA methylation analysis, gene expression analysis, mutation analysis, proteomic profiling, high performance liquid chromatography, immunoenzyme technique, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 26, 2026, 5:46 PM EDT